Survival and prognostic factors of women with advanced ovarian cancer and complete response after a carboplatin-paclitaxel chemotherapy

Gianpiero Polverino, Fabio Parazzini, Giovanna Stellato, Giovanna Scarfone, Sonia Cipriani, Giorgio Bolis

Research output: Contribution to journalArticle

Abstract

Objective. We evaluated the characteristics and determinants of 5-year survival in ovarian cancer patients with complete response after first line treatment who entered a randomised study comparing two different chemotherapeutic schedules. Methods. This analysis included 232 ovarian cancer patients with complete response after first line surgery and chemotherapy coming from a large randomised trial comparing the effect of different doses of paclitaxel combined with fixed doses of carboplatin. Results. The 5-year overall survival in patients was 57.3%. The difference in 5-year survival for age 1 cm: these differences were statistically significant (P <0.006). Conclusion. This study shows that in women with ovarian cancer and complete response after first line surgery and chemotherapy, age, histotype and residual tumour after surgery are determinants of 5-year overall survival.

Original languageEnglish
Pages (from-to)343-347
Number of pages5
JournalGynecologic Oncology
Volume99
Issue number2
DOIs
Publication statusPublished - Nov 2005

Fingerprint

Carboplatin
Paclitaxel
Ovarian Neoplasms
Drug Therapy
Survival
Residual Neoplasm
Appointments and Schedules
Therapeutics

Keywords

  • Ovarian cancer
  • Prognostic factors
  • Survivals complete responses

ASJC Scopus subject areas

  • Obstetrics and Gynaecology
  • Oncology

Cite this

Survival and prognostic factors of women with advanced ovarian cancer and complete response after a carboplatin-paclitaxel chemotherapy. / Polverino, Gianpiero; Parazzini, Fabio; Stellato, Giovanna; Scarfone, Giovanna; Cipriani, Sonia; Bolis, Giorgio.

In: Gynecologic Oncology, Vol. 99, No. 2, 11.2005, p. 343-347.

Research output: Contribution to journalArticle

@article{7d5b2ebf1d2146ed8a3a015205a56fac,
title = "Survival and prognostic factors of women with advanced ovarian cancer and complete response after a carboplatin-paclitaxel chemotherapy",
abstract = "Objective. We evaluated the characteristics and determinants of 5-year survival in ovarian cancer patients with complete response after first line treatment who entered a randomised study comparing two different chemotherapeutic schedules. Methods. This analysis included 232 ovarian cancer patients with complete response after first line surgery and chemotherapy coming from a large randomised trial comparing the effect of different doses of paclitaxel combined with fixed doses of carboplatin. Results. The 5-year overall survival in patients was 57.3{\%}. The difference in 5-year survival for age 1 cm: these differences were statistically significant (P <0.006). Conclusion. This study shows that in women with ovarian cancer and complete response after first line surgery and chemotherapy, age, histotype and residual tumour after surgery are determinants of 5-year overall survival.",
keywords = "Ovarian cancer, Prognostic factors, Survivals complete responses",
author = "Gianpiero Polverino and Fabio Parazzini and Giovanna Stellato and Giovanna Scarfone and Sonia Cipriani and Giorgio Bolis",
year = "2005",
month = "11",
doi = "10.1016/j.ygyno.2005.06.008",
language = "English",
volume = "99",
pages = "343--347",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - Survival and prognostic factors of women with advanced ovarian cancer and complete response after a carboplatin-paclitaxel chemotherapy

AU - Polverino, Gianpiero

AU - Parazzini, Fabio

AU - Stellato, Giovanna

AU - Scarfone, Giovanna

AU - Cipriani, Sonia

AU - Bolis, Giorgio

PY - 2005/11

Y1 - 2005/11

N2 - Objective. We evaluated the characteristics and determinants of 5-year survival in ovarian cancer patients with complete response after first line treatment who entered a randomised study comparing two different chemotherapeutic schedules. Methods. This analysis included 232 ovarian cancer patients with complete response after first line surgery and chemotherapy coming from a large randomised trial comparing the effect of different doses of paclitaxel combined with fixed doses of carboplatin. Results. The 5-year overall survival in patients was 57.3%. The difference in 5-year survival for age 1 cm: these differences were statistically significant (P <0.006). Conclusion. This study shows that in women with ovarian cancer and complete response after first line surgery and chemotherapy, age, histotype and residual tumour after surgery are determinants of 5-year overall survival.

AB - Objective. We evaluated the characteristics and determinants of 5-year survival in ovarian cancer patients with complete response after first line treatment who entered a randomised study comparing two different chemotherapeutic schedules. Methods. This analysis included 232 ovarian cancer patients with complete response after first line surgery and chemotherapy coming from a large randomised trial comparing the effect of different doses of paclitaxel combined with fixed doses of carboplatin. Results. The 5-year overall survival in patients was 57.3%. The difference in 5-year survival for age 1 cm: these differences were statistically significant (P <0.006). Conclusion. This study shows that in women with ovarian cancer and complete response after first line surgery and chemotherapy, age, histotype and residual tumour after surgery are determinants of 5-year overall survival.

KW - Ovarian cancer

KW - Prognostic factors

KW - Survivals complete responses

UR - http://www.scopus.com/inward/record.url?scp=27144504248&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=27144504248&partnerID=8YFLogxK

U2 - 10.1016/j.ygyno.2005.06.008

DO - 10.1016/j.ygyno.2005.06.008

M3 - Article

C2 - 16051334

AN - SCOPUS:27144504248

VL - 99

SP - 343

EP - 347

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 2

ER -